My current employer, Precision Health Economics, has posted an interesting research brief describing how traditional notions of value may not be capturing the full value patients receive from oncology treatments.
A brief description is below but do check out the full report.
As health care spending continues to rise, payers and providers struggle to accurately measure value to patients, and with health systems all over the world shifting towards paying for value, not just volume, these efforts have never been more important.
Learn about PHE’s groundbreaking studies that have helped define the value of new oncology drugs, and why a variety of global stakeholders have turned to PHE to assist them in defining value in cancer care.